Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 418M | 17.7% |
| Gross Profit | 22M | 211% |
| Cost of Revenue | 396M | 5.4% |
| Operating expense | 234M | 2.9% |
| Net Income | -12M | 278% |
| EBITDA | 680,000 | 98.6% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 4.07B | 0.1% |
| Total Liabilities | 2.54B | 2.4% |
| Total Equity | 1.53B | 4% |
| Shares Outstanding | 77M | 0.4% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | 40M | 156.4% |
| Cash from investing | -322M | 497% |
| Cash from financing | -94M | 126.1% |
EPS
Financial Highlights for Integra Lifesciences in Q2 '24
Integra Lifesciences reported a revenue of 418M, which is a 17.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 22M, marking a 211% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 396M, a 5.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 234M, showing a -2.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -12M, showing a -278% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 680,000, showing a -98.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Integra Lifesciences faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
